Jong Kun Dang Pharmaceutical Corp. (CEO Kim Young-joo) announced on February 6th that it has signed an exclusive domestic sales contract with Bayer Korea (CEO Lee Jin-ah) for Nexavar (active ingredient: sorafenib tosilate (un differentiated)) and Stivarga (active ingredient: regorafenib), treatments for progressive hepatocellular carcinoma.
Through this agreement, Jong Kun Dang will be responsible for the exclusive distribution, sales, and marketing of Nexavar and Stivarga in domestic hospitals and clinics starting from February. Nexavar and Stivarga are targeted therapies for hepatocellular carcinoma, with proven efficacy and safety profiles through various clinical trials. In particular, Stivarga has become established as a sequential treatment option eligible for insurance coverage for both first-line and second-line treatment of hepatocellular carcinoma in Korea, as its insurance coverage was expanded in 2018 as the first second-line treatment for liver cancer in the country.
Kim Young-joo, CEO of Jong Kun Dang, said, "We are strengthening our expertise in the oncology sector by establishing a dedicated anti-cancer organization. With the exclusive distribution of Nexavar and Stivarga, we will have a stronger anti-cancer portfolio and further expand our presence in the domestic anti-cancer market."
Lee Jin-ah, CEO of Bayer Korea, said, "We are pleased to supply Bayer products with Jong Kun Dang, which has differentiated competitiveness in the oncology field based on the long-standing trust between the two companies. Through this partnership, we will be able to provide treatment options such as Nexavar and Stivarga more smoothly, thereby contributing to improving the quality of life for domestic liver cancer patients."
Meanwhile, Jong Kun Dang and Bayer Korea have been co-selling the antibiotics Ciproby and Avelox since 2005, and Kerendia, a treatment for chronic kidney disease with type 2 diabetes, since 2024. Jong Kun Dang is also the sole distributor of Bayer Korea's cardiovascular drugs, Aspirin Protect and Adalat Oros, continuing a successful partnership.
[Copyright (c) Global Economic Times. All Rights Reserved.]
